NBP (NovaBridge Biosciences) 3-Year Share Buyback Ratio: -11.60% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NBP NovaBridge Biosciences NBP
30 GF Score
Price $1.80
! 2 Warning Signs
View Full Analysis

What is NovaBridge Biosciences 3-Year Share Buyback Ratio?

NovaBridge Biosciences NBP 30 3-Year Share Buyback Ratio is -11.60 as of Jun. 2026. GuruFocus rates NBP with a GF Score™ of 30/100. The stock has 2 warning signs investors should review. Among 1,188 Biotechnology companies, NovaBridge Biosciences ranks better than 50.51% on this metric.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. NovaBridge Biosciences's current 3-Year Share Buyback Ratio was -11.60%.

The historical rank and industry rank for NovaBridge Biosciences's 3-Year Share Buyback Ratio or its related term are showing as below:

NBP' s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -12.8   Med: -9.4   Max: -0.7
Current: -11.6

During the past 9 years, NovaBridge Biosciences's highest 3-Year Share Buyback Ratio was -0.70%. The lowest was -12.80%. And the median was -9.40%.

NBP's 3-Year Share Buyback Ratio is ranked better than
50.51% of 1188 companies
in the Biotechnology industry
Industry Median: -11.85 vs NBP: -11.60

NovaBridge Biosciences (NAS:NBP) 3-Year Share Buyback Ratio Explanation

A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.


Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.


NovaBridge Biosciences 3-Year Share Buyback Ratio Related Terms


NBP vs PEPG, DTIL, CRBP: 3-Year Share Buyback Ratio Comparison

For the Biotechnology subindustry, NovaBridge Biosciences's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NovaBridge Biosciences 3-Year Share Buyback Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NovaBridge Biosciences's 3-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where NovaBridge Biosciences's 3-Year Share Buyback Ratio falls into.


NBP
30GF Score
NovaBridge Biosciences NBP
3-Year Share Buyback Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NovaBridge Biosciences 3-Year Share Buyback Ratio Calculation

This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

What does a 3-Year Share Buyback Ratio of -11.60 mean?
NovaBridge Biosciences (NBP) has a 3-Year Share Buyback Ratio of -11.60 as of Jun. 2026. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for NovaBridge Biosciences and its competitors. According to the industry distribution chart, NovaBridge Biosciences ranks #588 out of 1188 companies in the Biotechnology industry, placing it in the top 49.5%.
Is NovaBridge Biosciences' 3-Year Share Buyback Ratio too high?
NovaBridge Biosciences' current 3-Year Share Buyback Ratio is -11.60. Based on the distribution chart, NovaBridge Biosciences ranks #588 out of 1188 companies in the Biotechnology industry, which is above the industry midpoint. Overall, NovaBridge Biosciences has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does NovaBridge Biosciences' 3-Year Share Buyback Ratio compare to PEPG and DTIL?
According to the Biotechnology industry distribution chart, NovaBridge Biosciences ranks #588 out of 1188 companies for 3-Year Share Buyback Ratio. This puts NovaBridge Biosciences in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Biotechnology company?
A good 3-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for NovaBridge Biosciences and its competitors. NovaBridge Biosciences's current 3-Year Share Buyback Ratio is -11.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NovaBridge Biosciences stock overvalued right now?
NovaBridge Biosciences (NBP) has a current 3-Year Share Buyback Ratio of -11.60. The current 3-Year Share Buyback Ratio is -11.60. NovaBridge Biosciences' overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For NovaBridge Biosciences (NBP), the current 3-Year Share Buyback Ratio is -11.60 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NovaBridge Biosciences Business Description

Other Exchanges 0VY:Germany
Address 2440 Research Boulevard, Suite 400, Rockville, MD, USA, 20850
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.
30GF Score

Get the complete analysis for NBP

3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.80
Price